MOULLIER P,SNYDER R O.International efforts for recombinant adeno-associated viral vector reference standards[J].Molecular therapy: The Journal of the American Society of Gene Therapy,2008,16(7):1185-1188.
[2]
SNYDER R O,FLOTTE T R.Production of clinical-grade recombinant adeno-associated virus vectors[J].Current opinion in biotechnology,2002,13(5):418-423.
[3]
BAINBRIDGE J W B,SMITH A J,BARKER S S,et al.Effect of gene therapy on visual function in Leber’s congenital amaurosis[J].N Engl J Med,2008,358(21):2240-2248.
[4]
MAGUIRE A M, HIGH K A,AURICCHIO A,et al.Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: A phase1 dose-escalation trial[J].Lancet,2009,374(9701):1597-1605.
[5]
MAGUIRE A M,SIMONELLI F,PIERCE E A,et al.Safety and efficacy of gene transfer for Leber’s congenital amaurosis[J].N Engl J Med,2008,358(21):2240-2248.
[6]
VELDWIJK M R,SCHIEDLMEIER B,KLEINSCHMIDT J A,et al.Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helper virus-free adeno-associated viral vector stocks[J].Eur J Cancer,1999,35(7):1136-1142.
[7]
GRIMM D,KERN A,PAWLITA M,et al.Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2[J].Gene Therapy,1999,6(7):1322-1330.
[8]
SUMMERFORD C,SAMULSKI,R J.Viral receptors and vector purification: New approaches for generating clinical-grade reagents[J].Nat Med,1999,5:587-588.
VELDVIJK M R,TOPALY J,LAUFS S,et al.Development and optimization of a real- time quantitative PCR-based method for the titration of AAV-2vector stocks[J].Mol Ther,2002,6(2):272-278.
[12]
AURNHAMMER C,HAASE M,MUETHER N,et al.Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences[J].Hum Gene Ther Methods,2012,23(1):18-28.
[13]
FAGONE P,WRIGHT J F,NATHWANI,et al.Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods[J].Hum Gene Ther Methods,2011,23(1):1-7.
[14]
MAYGINNES J P,REED S E,BERG H G,et al.Quantitation of encapsidated recombinant adeno-associated virus DNA in crude cell lysates and tissue culture medium by quantitative,real-time PCR[J].Journal of Virological Methods,2006,137(2):193-204.
[15]
ROHR U P,WULF M A,STAHN S,et al.Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR[J].Journal of Virological Methods,2002,106(1):81-88.
[16]
YAN Z,ZAK R,ZHANG Y,et al.Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes[J].J Virol,2005,79(1):364-379.
[17]
MCALISTER V J,OWENS R A,VICTOR J.Preferential integration of adeno-associated virus type 2 into a polypyrim- idine/polypurine-rich region within AAVS1[J].J Virol,2007,81(18):9718-9726.
[18]
DAYA S,BERNS K I.Gene therapy using adeno-associated virus vectors[J].Clinical microbiology reviews,2008,21(4):583-593.
[19]
MUSATOV S,ROBERTS J,PFAFF D,et al.A cis-acting element that directs circular adeno- associated virus replication and packaging[J].Journal of Virology,2002,76(24):12792-12802.
[20]
BARNETT D, GRANGER V, KRAAM J,et al.Reduction of intra-and interlaboratory variation in CD34+ stem cell enumeration using stable test material,standard protocols and targeted training[J].Br J Haematol,2000,108(4):784-792.
[21]
CHEN J C,BIGELOW N,DAVIS B H.Proposed flow cytometric reference method for the determination of erythroid F-cell counts[J].Cytometry,2000,42(4):239-246.
[22]
RUMKE C L.The statistically expected variability in differential leukocyte counting[M].KOEPKE J A.Differen-
[23]
tial Leukocyte Counting.Illinois:College of American Pathologists,1977:39-45.
LOCK M,MCGORRAY S,AURICCHIO A,et al.Characterization of a recombinant adeno-associated virus type 2 reference standard material[J].Hum Gene Ther,2010,21(10):1273-1285.
[26]
WANG Z,MA H I,LI J,et al.Rapid and highly efficient transduction by double-stranded adeno- associated virus vectors in vitro and in vivo[J].Gene Ther,2003,10(26):2105-2211.
[27]
MCCARTY D M,FU H,MONAHAN P E,et al.Adenoassociated virus terminal repeat(TR)mutant generates self complementary vectors to overcome the rate-limiting step to transduction in vivo[J].Gene Ther,2003,10(26):2112-2118.
[28]
FLOTTE T R,SOLOW R,OWENS R A,et al.Gene expression from adeno-associated virus vectors in airway epithelial cells[J].American Journal of Respiratory Cell and Molecular Biology,1992,7(3):349-356.
[29]
RUFFING M,ZENTGRAF H,KLEINSCHMIDT J A.Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells[J].J Virol,1992,66(12):6922-6930.
[30]
ZOLOTUKHIN S,BYRNE B J,MASON E,et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield[J].Gene Ther,1999,6(6):973-985.
[31]
CLARK K R,LIU X,MCGRATH J P,et al.Highly purified recombinant adeno-associated virus vectors are bio-logically active and free of detectable helper and wild type viruses[J].Hum Gene Ther,1999,10(6):1031-1039.
[32]
ZHEN Z,ESPINOZA Y,BLEU T,et al.Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events[J].Hum Gene Ther,2004,15(7):709-715.
MAYFIELD T L,KORYTOV I,FRANCIS J D,et al.Detection and quantification of rcAAV in rAAV stocks by real-time qPCR[J].Molecular Therapy,2006,13:S196-S197.
